摘要
目的探讨支气管炎片联合沙美特罗替卡松粉吸入剂治疗咳嗽变异性哮喘的临床疗效。方法选取2014年5月—2015年2月上海中医药大学附属普陀医院呼吸内科收治的咳嗽变异性哮喘患者92例,按治疗方法的不同分为对照组和治疗组,每组各46例。对照组吸入沙美特罗替卡松粉吸入剂,1吸/次,早晚各1次。治疗组在对照组基础上口服支气管炎片,2~5片/次,3次/d。两组患者均治疗2周,并进行6个月的随访。观察两组的临床疗效,同时比较两组治疗的咳嗽评分及肺功能情况。结果治疗后,对照组和治疗组的总有效率分别为82.61%、95.65%,两组比较差异有统计学意义（P〈0.05）。治疗后,两组患者咳嗽评分均显著降低,而1秒用力呼气容积（FEV1）和最大呼气流量（PEF）均显著升高,同组治疗前后比较差异有统计学意义（P〈0.05）;且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义（P〈0.05）。结论支气管炎片联合沙美特罗替卡松粉吸入剂治疗咳嗽变异性哮喘具有较好的疗效,能改善患者肺功能,缓解咳嗽症状,具有一定的临床推广应用价值。
Objective To investigate the clinical effect of Zhiqiguanyan Tablets combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation in treatment of cough variant asthma. Methods Patients（92 cases） with cough variant asthma in Department of Respiratory of Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from May 2014 to February 2015 were enrolled in this study. According to the different treatment plans, the patients were divided into the control and treatment groups, and each group had 46 cases. Patients in the control group were inhalation administered with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation, twice daily, 1 suck/time, each time in the morning and evening. Patients in the treatment group were po administered with Zhiqiguanyan Tablets on the basis of the control group, 2—5 tablets/time, three times daily. Patients in two groups were treated for 2 weeks, and followed up for 6 months. After treatment, the clinical efficacies in two groups were evaluated, and the changes of cough scores and pulmonary function indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.61% and 95.65%, respectively, and there was difference between two groups（P〈0.05）. After treatment, the cough scores in two groups were significantly decreased, but FEV1 and PEF in two groups were significantly increased, and the difference was statistically significant in the same group（P〈0.05）. And the observational indexes in the treatment group were obviously better than those in the control group, with significant difference between two groups（P〈0.05）. Conclusion Zhiqiguanyan Tablets combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation have clinical curative effect in treatment of cough variant asthma, and can improve pulmonary function, relieve cough symptom, which has a certain clinical application value.
出处
《现代药物与临床》
CAS
2016年第7期982-985,共4页
Drugs & Clinic
关键词
支气管炎片
沙美特罗替卡松粉吸入剂
咳嗽变异性哮喘
咳嗽评分
肺功能指标
Zhiqiguanyan Tablets
Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation
cough variant asthma
cough scores
pulmonary function indexes
